Underuse of statins in MASLD despite population-based associations with lower liver stiffness - PubMed
5 hours ago
- #liver stiffness
- #statin
- #MASLD
- Statins, typically used for cardiovascular disease (CVD) prevention, may also offer hepatoprotective benefits.
- The study found underuse of statins in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD), despite higher CVD risk.
- Participants with MASLD had a higher predicted 10-year CVD risk but were less likely to use statins compared to those without MASLD.
- Statin use was associated with a lower prevalence of MASLD and elevated liver stiffness.
- The highest statin dosage category was linked to reduced prevalence of MASLD and elevated liver stiffness.
- The findings highlight a missed opportunity in optimizing statin use for both CVD prevention and potential liver health benefits in MASLD patients.